摘要
Objective To compare the efficacy,response and survival between high-dose melphalan(HDM)and cyclophosphamide+etoposide+busulfan(CVB)as the conditioning regimen in autologous stem cell transplantation(ASCT)for newly diagnosed multiple myeloma(NDMM).Methods 123 consecutive NDMM patients who had received PAD induction with subsequent ASCT from Jan 2011 to Aug 2017 were retrospectively studied.The CVB group and HDM group had 82 and 41 patients respectively.Results①No differences existed between these 2 groups in non-hematological side effects.
作者
GU Jingli
谷景立(Affil Hosp,Sun Yat-sen Univ,Guangzhou 510080)